PATENT CLAIM ANALYSIS

Application Number: 16041167
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["424", "208100"]

Abstract:
Methods for inducing safe and effective immune response against multiple clades of Human Immunodeficiency Virus (HIV) infection in human subjects are described. The methods involve heterologous vaccine combinations of adenovirus serotype 26 expression vectors expressing at least three mosaic HIV antigens with at least one isolated HIV gp140 protein.

Claim (Index 2):
The method of  claim 1 , further comprising:\n (5) administering to the subject, about 42-60 weeks after (1), the first boosting composition at a total dose of about 125 \u03bcg to 350 \u03bcg, of the at least one isolated HIV envelope glycoprotein; and (6) administering to the subject, together with (5), the second boosting composition at a total dose of about 5\u00d710 9  to about 1\u00d710 11  vp of the Ad26 vectors; or administering to the subject, together with (5), the second alternative boosting composition at a total dose of about 10 7  to about 10 9  pfu of the MVA vectors.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 95.0
- Lexical Diversity: 1.12766
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15968834', '14863808', '15693650', '15380123', '13130018']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7199593684037089
- 35 USC 102 Novelty (BERT): 0.593408868279914
- Combined Prediction Score: 0.7073043183913295
- Mean Citation Score: 472.678518
- Max Citation Score: 600.1256
- Similarity Product: 398.04308694047927

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test